

The French leader in specialised pathology, Biomnis, completes the restructuring of its capital

With the backing of the European investment fund, Duke Street, the Biomnis group confirms its ambitions.

Initiated last January with the withdrawal of Fondation Mérieux, the capital restructuring project of the Biomnis group, in which Jean-Louis Oger no longer wished to remain the main individual shareholder, has finally resulted in the choice of a financial partner.

The capital investment firm, Duke Street, has purchased the French leader in specialised medical pathology for an enterprise value of €217 million.

With the support of this new reference shareholder, Biomnis is approaching the future with confidence and determination under the aegis of its new Chairman of the board, Pierre-Yves Guiavarch. Aged 47, a qualified pathologist and previously the director of the Rhône Alpes Region of Générale de Santé, Pierre-Yves Guiavarch is taking on the operational management of the group, with Jean-Louis Oger remaining a minority shareholder and Chairman of the Supervisory Board.

This new stage is consistent with the quality of the services and partnership with first-line pathologists, in private and hospital laboratories. It is also consistent with the fundamental values of Biomnis: expertise, innovation, quality, proximity and the concept of service, which will remain at the heart of the group's development strategy.

In this way, Biomnis is confirming its ambitions on an evolving market: strengthening its leading position in specialised pathology, in France and internationally, and keeping its rank as a "responsible" player in economic terms in a context of increased healthcare expenditure control.

About Biomnis

www.biomnis.com

The French leader in the specialised medical pathology sector, Biomnis generates a consolidated turnover of approximately €220 million and operates around ten laboratories in France and in Europe. The group has over 1600 employees and offers a very wide range of tests, including all specialised procedures for which it has obtained all the approvals required.

A major player in the United Kingdom and the Middle East, Biomnis is continuing its international development. Its strategy is based on very advanced technical expertise and the control of the peripheral functions of the sector, making it possible to improve quality of service, such as logistics via its subsidiary TSE Express Médical, or I.T., via its subsidiary Openlab.

About Duke Street

www.dukestreet.com

A leading European investor, Duke Street is a capital investment firm specialised in enterprise transfer with a leverage effect (MBOs and MBIs) essentially in the United Kingdom and France. Founded in London in 1988 in Hambro bank, independent since 1998 and based in Paris since 2002, Duke Street manages total assets of €2 billion and invests in medium-sized businesses worth €50 to 500 million.

Media contact

Béatrice Peyrelongue - Thomas Marko & Associés

Tel.: +33 (0)1 44 90 87 43 – Fax: +33 (0)1 44 90 82 61 – E-mail: beatrice.p@tmarkoagency.com